COVID-19, the human coronavirus disease caused by SARS-CoV-2, was reported for the first time in Wuhan, China in late 2019. COVID-19 has no preventive vaccine or proven standard pharmacological treatment, and consequently, the outbreak swiftly became a pandemic affecting more than 215 countries around the world. For the diagnosis of COVID-19, the only reliable diagnostics is a qPCR assay. Among other diagnostic tools, the CRISPR-Cas system is being investigated for rapid and specific diagnosis of COVID-19. The CRISPR-Cas-based methods diagnose the SARS-CoV-2 infections within an hour. Apart from its diagnostic ability, CRISPR-Cas system is also being assessed for antiviral therapy development; however, till date, no CRISPR-based therapy has been approved for human use. The Prophylactic Antiviral CRISPR in huMAN cells (PAC-MAN), which is Cas 13 based strategy, has been developed against coronavirus. Although this strategy has the potential to be developed as a therapeutic modality, it may face significant challenges for approval in human clinical trials. This review is focused on describing potential use and challenges of CRISPR-Cas based approaches for the development of rapid and accurate diagnostic technique and/or a possible therapeutic alternative for combating COVID-19. The assessment of potential risks associated with use of CRISPR will be important for future clinical advancements.
【저자키워드】 SARS-CoV-2, coronavirus, Diagnosis, pandemic (COVID-19), CRISPR, therapeutic, 【초록키워드】 COVID-19, coronavirus disease, antiviral therapy, Vaccine, pandemic, therapy, Infection, diagnostic, outbreak, diagnose, pharmacological treatment, potential risk, approval, human clinical trials, approach, country, Cell, Wuhan, China, combating, caused, reported, investigated, approved, affecting, CRISPR-Ca, diagnosis of COVID-19, the SARS-CoV-2, 【제목키워드】 COVID-19, Therapeutics, Potential, CRISPR-Ca,